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Abstract
Several studies have pointed out a significant association between rheumatoid arthritis (RA) and accelerated atherosclerosis. At the
best of our knowledge, no such study has been carried out in a large Italian series and, in this study, we aimed to investigate the
prevalence of both subclinical atherosclerosis and history of cardiovascular events (CVEs), in patients consecutively admitted from
January 1, 2015 to December 31, 2015 to Rheumatology Units throughout the whole Italy.
Centers members of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) were invited to enrol patients
consecutively admitted from January 1, 2015 to December 31, 2015 and satisfying American College of Rheumatology/ European
League Against Rheumatism criteria for RA and to investigate each of them for: traditional cardiovascular risk factors: sex, age,
smoking habit, total cholesterol, triglycerides, glycaemia, high blood pressure, metabolic syndrome (MS), type 2 diabetes (T2D); RA
features: disease duration as assessed from the first symptom, disease activity as evaluated by DAS28, radiographic damage as
assessed by hands and feet x-ray, and previous joint surgery; prevalence of both subclinical atherosclerosis and history of CVEs.
Eight centers participated to the study. From January 1, 2015 to December 31, 2015, the 1176 patients, who had been
investigated for all the items, were enrolled in the study. They were mostly women (80.52%), with a median age of 60 years (range,
18–91 years), a median disease duration of 12 years (range, 0.8–25 years), seropositive in 69.21%. Nineteen percent were in
remission; 17.51% presented low disease activity; 39.45% moderate disease activity; 22.61% high disease activity.
Eighty-two patients (6.9%) had a history for CVEs (58 myocardial infarction, 38 heart failure, 10 ischemic transitory attack, and 7
stroke). This figure appears to be lower than that reported worldwide (8.5%). After excluding the 82 patients with a history of CV
events, subclinical atherosclerosis was detected in 16% of our patients, (176 patients), a figure lower than that reported worldwide
(32.7%) and in previous Italian studies.
This is the first Italian multicenter study on subclinical and clinical atherosclerosis in patients with RA. We pointed out a low
prevalence of both subclinical atherosclerosis and history of CV events.
Abbreviations: ACPA = anti-citrullinated protein antibody, bDMARD = biologic disease-modifying anti-rheumatic drug, CHF =
congestive heart failure, CRP =C-reactive protein, csDMARD = conventional synthetic disease-modifying anti-rheumatic drug, CV =
cardiovascular, CVAs = cerebrovascular accidents, CVEs = cardiovascular events, DAS28 = disease activity score in 28 joints,
GIRRCS = Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale, HBP = high blood pressure, ISTAT = Italian National
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Institute of Statistics, ldCCSs = low dose corticosteroids, MI = myocardial infarction, MS = metabolic syndrome, RA = rheumatoid
arthritis, RF = rheumatoid factor, T2D = type 2 diabetes.
Keywords: cardiovascular events, inflammatory process, rheumatoid arthritis, subclinical atherosclerosis, traditional
cardiovascular risk factor
1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
characterized by an increased risk of mortality, as compared with
general population, mainly due to cardiovascular events
(CVEs).[1–3] In fact, a large percentage of RA patients experience
myocardial infarction (MI), cerebrovascular accidents (CVAs),
and congestive heart failure (CHF) during their life.[4–6]
Furthermore, an increased prevalence of subclinical atheroscle-
rosis as evidenced by carotid artery plaques, has been observed in
these patients, and this subclinical condition may allow to
identify those RA patients with a higher risk to develop CVEs.[4,7]
In addition, it has been pointed out that “traditional”
cardiovascular (CV) risk factors, such as high blood pressure
(HBP), type 2 diabetes (T2D), and metabolic syndrome (MS) are
underestimated in RA patients and therefore untreated,[8–11] thus
contributing to the increased CV risk, despite specific interna-
tional recommendations were developed.[12,13] To date, the
causes of accelerated atherosclerosis have not been fully
elucidated. In fact, specific features of RA, including systemic
inflammatory process and disease activity, seem to be involved in
promoting CV risk in addition to traditional risk factors.[14–16]
It has been shown that CVmortality in RA has distinct patterns
among different countries; RA has been reported to present both a
lower prevalence and a milder disease course in Italy and in other
Mediterranean countries with respect to North European
countries.[17–19] At the best of our knowledge, no study has been
carried out in a large Italian series of RA patients in order to
evaluate the risk of CVEs and subclinical atherosclerosis in Italian
RApatients. In thiswork,we investigated the presence ofCVEsand
subclinical atherosclerosis in a cohort ofRApatients enrolled in the
multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia
Clinica e Sperimentale) observational study (RA-GIRRCS Study),
evaluating thepossibleassociationsamongboth traditionalCVrisk
factors and disease specific features and the evidence of CVEs and
subclinical atherosclerosis. Furthermore, due to the differences
pointed out inRApopulations across differentWorldwide nations,
mainly in comorbidities and long-term outcome,[20] an evaluation
between our data of prevalence of both subclinical atherosclerosis
andhistoryofCVEs, and the availableRA literaturewasperformed
in order to discuss possible differences.
2. Patients and methods
2.1. Study design, inclusion criteria, and data collection
Eight tertiary Rheumatologic units, throughout the whole Italy,
with high experience in management of RA patients as well as in
observational studies were involved. The reports of the first
scheduled visit of each patient, satisfying the American College of
Rheumatology/ EuropeanLeagueAgainst Rheumatism criteria for
RA,[21,22] and visited from January 1, 2015 to December 31, 2015
were reviewed. The patients were evaluated for traditional CV risk
factors, history of CVEs and subclinical atherosclerosis. CVEs
were defined as history of MI and/or CHF and/or CVAs. The
prevalence of each condition and their cumulative prevalence was
compared with those registered in Italian general population
matched for sex and age by the Italian National Institute of
Statistics (ISTAT, www.istat.it). Subclinical atherosclerosis was
definedas the presence of carotid plaqueas assessed by carotidand/
or peripheral arteries ultrasound imaging. Its prevalence was
comparedwith that registered in control subjects from3 studies on
subclinical atherosclerosis in Italian patients with RA, Sjogren
syndrome, or systemic lupus erythematosus.[23–26] Smoking habit,
evidence of HBP, T2D, and MS as well as serum levels of total
cholesterol and triglycerides were recorded, at the first visit.
Disease activity was assessed by Disease Activity Score in 28 joints
(DAS28).[27] Furthermore, disease duration from the first disease
symptom, radiographic damage evaluated as the presence of
erosions/joint narrowing at hands or feet, history of joint surgery,
C reactive protein (CRP) and rheumatoid factor (RF), and/or anti-
citrullinated protein antibody (ACPA) were also registered. Extra-
articular features were assessed, the diagnosis of these disease
manifestationswas basedon those used in previous studies.[19] The
extra-articular manifestations considered were: secondary Sjögren
syndrome with clinical evidence of dry eyes/mouth, rheumatoid
nodules, vasculitis, pulmonary involvement, cutaneous, and
neurologic manifestations. The patients were divided in 5 groups,
according with their therapeutic regimen: single conventional
synthetic disease-modifying anti-rheumatic drug (csDMARD)+
lowdose corticosteroids (ldCCSs); combination of≥2 csDMARDs
without CCSs; csDMARD(s)+ ldCCSs+Biologic DMARD
(bDMARD); sDMARD(s)+DMARD (bDMARD) without corti-
costeroids (CCSs); other therapeutic regimens.
Both international and national recommendations for the
management of RA patients were strictly followed. The local
ethics committee (Comitato Etico Azienda Sanitaria Locale 1
Avezzano/Sulmona/L’Aquila, L’Aquila, Italy; protocol number
000331/17) approved the study, that was performed according to
the Good Clinical Practice guidelines and the Declaration of
Helsinki.Written informed consentwasobtained fromall patients.
2.2. Statistical analysis
Associations between subclinical atherosclerosis and CVEs and
any other demographic or clinical feature were assessed by
calculating the respective ORS. Covariates were selected from 2
main areas: traditional CV risk factors: sex, age, smoking habit,
serum levels of total cholesterol and triglycerides presence of MS,
T2D, andHBP;RA-related risk factors: DAS28values, duration of
the disease, presence of extra-articular disease, evidence of
radiographic damage, and history of joint surgery. We modeled
different statistical analyses, adjusted for sex and age, by
performing a logistic regression, to evaluate the possible
associations between each of these among these covariates and
both history of CVEs and presence of subclinical atherosclerosis.
Furthermore, we performed the same analysis in order to evaluate
the possible associations between the same set of variables and the
evidence of MI, CHF, and CVAs singularly considered. Models
fitting has been assessed carrying out a log-likelihood ratio Sidak
test, adjusted formultiple tests, with type I error set at 0.05. Due to
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the relative simple design and the expertise of the recruiting centers,
we had a low percentage of missing data, that could impair our
analyses. The analysis was performed using SPSS software (SPSS
for Windows, version 17.0, SPSS Inc., Chicago, IL).
3. Results
3.1. Baseline characteristics of evaluated RA patients
From January 1, 2015 to December 31, 2015, 1176, admitted to
8 GIRRCS centers, were enrolled in the study; the demographic
features of our cohort are shown in Table 1. They were mostly
women (80.52%), with a median age of 60 years (range, 18–91
years), a median disease duration of 12 years (range, 0.8–25
years), seropositive in 69.21%. Nineteen percent were
in remission; 17.51% presented low disease activity; 39.45%
moderate disease activity; 22.61% high disease activity. The
most common RA therapeutic strategies were csDMARD+
ldCCSs (24.60%) and sDMARD(s)+ ldCCSs+bDMARD
(34.70%). Methotrexate (MTX) and TNF inhibitors were
the most common sDMARD and bDMARD prescribed,
respectively.
As far as the traditional CV risk factors are concerned, 45.20%
presented a HBP, 32% reported smoking habit, 24.30% were
affected by MS, and 13.10% by T2D. Serum total cholesterol
resulted 196.31±48.82mg/dL (mean±SD), serum triglycerides
117.25±51.79mg/dL; blood glucose 92.60±33.36mg/dL. In
particular, 49.54% displayed a serum total cholesterol >200mg/
dL; 31.46% triglycerides >130mg/dL; 13.43% out of patients
displayed a glycaemia >110mg/dL. Furthermore, 5.4% were
affected by osteoporosis, 4.3% by thyroid diseases, 1.1% by
HBV infection, and 0.9% by HCV infection.
3.2. History of CVEs and related risk factors
Eighty-two patients (6.9%) had a history for CVEs (58 patients
myocardial infarction, 38 patients heart failure, 10 patients
ischemic transitory attack, 7 patients stroke). This prevalence is
higher than that reported in Italian National Institute of Statistics
(ISTAT, www.istat.it) (Table 2).
Univariate analyses (Table 3) pointed out significant associ-
ations between both some traditional CV risk factors and some
RA-related factors and history of CVEs. In particular, among the
former, older age (odds ratio [OR]: 1.06, 95% confidence
interval [CI]: 1.04–1.08, P< .001), male sex (OR: 2.73, 95% CI:
1.71–4.37, P< .001), MS (OR: 6.72, 95% CI: 4.20–10.77,
P< .001), T2D (OR: 5.71, 95% CI: 3.54–9.18, P< .001), HBP
(OR: 11.37, 95% CI: 5.63–22.95, P< .001) were each
significantly associated with previous CVEs. Among the latter,
a high disease activity (DAS28 >5.1) only was significantly
associated with the presence of CVEs (OR: 1.50, 95% CI: 1.27–
1.97, P= .042). Therefore, smoking habit, total cholesterol
values, disease duration, RF, ACPA, extra-articular disease, joint
surgery, and radiographic were not statistically associated with
history of CVEs. Of note, in multivariate analysis (Table 3), the
evidence of MS (OR: 2.54, 95% CI: 1.29–4.52, P= .005), T2D
(OR: 2.32, 95% CI: 1.29–4.29, P= .007), and HBP (OR: 4.92,
95%CI: 2.14–11.45, P< .001) as well as the high disease activity
(DAS28 >5.1) (OR: 1.31, 95% CI: 1.15–1.68, P= .003) were
significantly associated with previous CVEs, in our cohort of RA
patients. Furthermore, by univariate and multivariate analyses,
we evaluated the possible association among the identified
variables and evidence of MI, CHF, and CVAs (additional
Table 1, http://links.lww.com/MD/B905 additional Table 2,
http://links.lww.com/MD/B905 additional Table 3, http://links.
lww.com/MD/B905).
3.3. Subclinical atherosclerosis and its associations
After excluding the 82 patients with a history of CV events,
subclinical atherosclerosis was detected in 16% of our patients,
(176 patients), it resulted higher than those observed in control
groups from Italian studies on other diseases reported in those
studies.[23–26]
Table 1
Demographic and clinical features of the evaluated patients.
Patients 1176
Gender (female/male) 80.52%/19.48%
ACR 1987 classificative criteria 74.1%
ACR/EULAR 2010 classificative criteria 93.5%
Age, y
Mean±SD 60.38±12.84
Median (range) 60 (range, 18–91)
RA clinical features
Disease duration, y
Mean±SD 12.35±9.61
Median (range) 12 (range, 0.8–25)
<1 y 5.50%
between 1 and 5 y 21.50%
between 5 and 10 y 22.00%
≥10 y 46.00%
RF and/or ACPA 69.21% (1176 pts)
Radiologic damage 46.10% (1165 pts)
Joint surgery 10.12% (1176 pts)
Extra-articular disease 16.32%
Disease activity_DAS28_first visit 4.83±17.48 (1118 pts)
Remission 19.40%
Low disease activity 17.51%
Moderate disease activity 39.45%
High disease activity 22.61%
HAQ-DI 0.94±0.78 (891 pts)
Traditional CV risk evaluation
Cholesterol, mg/dL 196.31±48.82 (998 pts)
Cholesterol >200mg/dL 49.54% (493 pts)
Triglycerides, mg/dL 117.25±51.79 (982 pts)
Triglycerides, mg/dL >130mg/dL 31.46% (309/982 pts)
Blood glucose, mg/dL 92.60±33.36 (1015 pts)
Blood glucose >110mg/dL 13.40% (136/1015 pts)
Smoking habit 32.90% (387/1176)
High blood pressure 45.74% (538/1176 pts)
Type 2 diabetes 13.09% (154/1176 pts)
Metabolic syndrome 24.06% (283/1176 pts)
RA therapeutic strategies
csDMARD(s)+ ldCCSs 24.60%
csDMARDs combination without CCSs 11.70%
csDMARD(s)+ ldCCSs+bDMARD 34.70%
csDMARD(s)+bDMARD without CCSs 17.39%
Other therapeutic strategies 11.51%
csDMARD 96.68%
MTX 78.38%
Other_csDMARDs 17.30%
bDMARDs 49.27%
TNF inhibitors 36.19%
Other bDMARDs 13.08%
ACPA=anti-citrullinated protein antibody, bDMARD=biologic disease-modifying anti-rheumatic
drug, CCSs= corticosteroids, csDMARD= conventional synthetic disease-modifying anti-rheumatic
drug, DAS28=Disease Activity Score in 28 joints, HAQ-DI=health assessment questionnaire
disability Index, MTX=methotrexate, RF= rheumatoid factor, ld= low dose, SDAI= simplified disease
activity index, TNF= tumor necrosis factor.
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At univariate analyses (Table 4), it was suggested that both
some traditional CV risk factors and some RA-related risk
factors resulted to be associated with the presence of subclinical
atherosclerosis. As far the traditional CV risk factors are
concerned, older age (OR: 1.08, 95% CI: 1.07–1.18, P< .001),
higher serum values of total cholesterol (OR:1.02, 95% CI:
1.01–1.16, P< .001), and triglycerides (OR: 1.01, 95% CI:
1.00–1.02, P< .001), MS (OR: 7.35, 95% CI: 5.35–10.13,
P< .001), T2D (OR: 5.71, 95% CI: 1.83–3.88, P< .001), HBP
(OR:10.82, 95% CI: 7.24–16.18, P< .001), were each
significantly associated with subclinical atherosclerosis. Con-
cerning the RA related risk factors, high disease activity (DAS28
>5.1) (OR: 2.85, 95% CI: 2.07–3.92, P< .001), and longer
disease duration (OR: 1.02, 95%CI: 1.01–1.04, P= .001) were
significantly associated with presence of subclinical atheroscle-
rosis. To date, remission (DAS28 <2.6) (OR: 0.45, 95% CI:
0.29–0.714, P= .001) was negatively associated with subclini-
cal atherosclerosis. Therefore, smoking habit, RF, ACPA,
extra-articular disease, joint surgery, and radiographic damage
were not associated with subclinical atherosclerosis. Interest-
ingly, in multivariate analysis, older age (OR: 1.069, CI 95%:
1.05–1.09, P< .001), MS (OR: 3.41, CI 95%: 2.16–5.40,
P< .001), and HBP (OR: 3.71, CI 95%: 2.23–6.17, P< .001)
and high disease activity (DAS28 >5.1) (OR: 2.11, CI 95%:
1.35–3.32, P= .001) were all significantly associated with the
presence of subclinical atherosclerosis.
Table 2
Specific prevalence rate ratios in RA GIRRCS cohort.
Age RA patients, number Subclinical atherosclerosis, number Specific prevalence rate (∗10,000 people)
35–44 94 0 0
45–54 210 19 90.5
55–64 383 54 161.0
65–74 304 78 258.6
35–74 991 151 158.4
Age RA patients, number CVEs, number Specific prevalence rate (∗10,000 people)
35–44 94 2 31.2
45–54 210 3 61.2
55–64 383 19 97.6
65–74 304 36 130.4
35–74 991 60 83.6
CVEs= cardiovascular events, GIRRCS=Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale, RA= rheumatoid arthritis
Table 3
CVEs univariate and multivariate analyses.
Univariate analyses OR SE P CI 95%
Gender 2.73 0.24 <.001 1.71–4.37
Age 1.06 0.01 <.001 1.04–1.08
Smoking habit 0.95 0.24 .85 0.21–4.60
Total cholesterol 0.99 0.03 .47 0.99–1.03
Triglycerides 1.01 0.02 .017 1.00–1.09
Metabolic syndrome 6.72 0.24 <.001 4.20–10.77
Type 2 diabetes 5.71 0.24 <.001 3.54–9.18
High blood pressure 11.37 0.36 <.001 5.63–22.95
Rheumatoid factor 1.15 0.25 .578 0.70–1.90
Anti-citrullinated protein antibodies 1.11 0.23 .628 0.71–1.75
Disease duration 0.97 0.01 .10 0.97–1.05
Remission 1.07 0.28 .803 0.62–1.87
Low disease activity 1.05 0.29 .856 0.59–1.89
Moderate disease activity 1.36 0.23 .156 0.88–2.17
High disease activity 1.50 0.33 .042 1.27–1.97
Joint surgery 0.44 0.52 .12 0.16–1.25
Radiographic damage 1.03 0.23 .87 0.66–1.63
Extra-articular disease 1.63 0.27 .07 0.94–2.77
Multivariate analysis OR SE P CI 95%
Gender 3.46 0.29 <.001 1.94–6.18
Age 1.01 0.01 .202 0.99–1.04
Triglycerides 1.00 0.02 .159 0.99–1.08
Type 2 diabetes 2.32 0.31 .007 1.29–4.29
Metabolic syndrome 2.54 0.39 .005 1.29–4.52
High blood pressure 4.92 0.43 <.001 2.14–11.45
High disease activity 1.31 0.38 .003 1.15–1.68
Bolded values indicate statistically significant results (P< .05).
CI= confidence interval, OR=odds ratio.
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4. Discussion
CV comorbidities are frequently associated with RA, strongly
influencing not only the clinical course and the outcome of these
patients, but also the therapeutic strategies in order to prevent the
occurrence of severe CVEs.[14,15] On this light, any study
exploring this clinical setting may provide useful information
about the evolution of clinical picture and the response to
treatments. Of interest, taking together our data it is possible to
point out a low prevalence of both subclinical atherosclerosis and
history of CV events when compared with other available
series.[5–7] In addition, in our multicenter GIRRCS observational
study, we show that, among the traditional CV risk factors, only
some of them were related with a history of CVEs, and, on other
hand, highest values of the DAS28 were associated with the
presence of both CVEs and/or subclinical atherosclerosis,
suggesting that not only the traditional CV risk factors but also
the disease activity is independently associated with the
development of CV complications.
In our study, we observed a low prevalence of these CV
comorbidities, both subclinical atherosclerosis and history of
CVEs when compared with other series.[5–7] Subclinical
atherosclerosis prevalence is lower than that reported in meta-
analysis of observational studies on the topic (16% vs 32.7%).[7]
In this study, an increased prevalence of carotid plaques in RA
patients has been shown.[7] Specifically, the authors analyzed 59
studies and reported that 32.7% of patients displayed this
feature.[7] As far as history of CVEs is concerned, several studies
and meta-analyses evaluated the prevalence of CVEs in RA
patients, and our prevalence seems lower than that reported in
meta-analysis of observational studies (6.9% vs 8.5%).[5,7]
Taking together these findings is not possible to address definitive
conclusions concerning the reduced prevalence that we observed
and future specific-designed studies are surely needed to fully
elucidated these possible differences, in RA population, across
different nations. In this context, it has been proposed that the
iniquity in access to health care system and stricter eligibility
criteria for treatments, such observed in countries with lower
socioeconomic welfare, may strongly influence the comorbidities
and long-term outcome in RA patients.[15]
Despite the well-known role of traditional CV risk factors, in
inducing CVEs and subclinical atherosclerosis in general
population, our analysis failed to show the expected association
among some of these factors and the development of CVEs. In
fact, we observed that only MS and HBP were associated with
both CVEs and subclinical atherosclerosis while T2D was
associated only with the evidence of CVEs. To date, multiple lines
of evidence confirmed a significant association between RA and
MS, T2D and HBP.[28,29] Furthermore, in this context, meta-
analytic data confirmed the role of traditional CV risk factors in
accelerating atherosclerosis, and thus CVEs, in RA patients.[30] In
addition, it has been shown that traditional CV risk factor may
not be optimally identified and treated, in RA patients, thus
contributing to the increase of CVEs risk.[31,32] Finally, NSAIDs
and steroids, frequently used in RA patients, may rise the systemic
blood pressure.[33,34]
Table 4
Subclinical atherosclerosis univariate and multivariate analyses.
Univariate analyses OR SE P CI 95%
Gender 1.26 0.18 .201 0.88–1.80
Age 1.08 0.08 <.001 1.07–1.18
Smoking habit 0.94 0.16 .72 0.69–1.29
Total cholesterol 1.02 0.02 <.001 1.01–1.16
Triglycerides 1.01 0.01 <.001 1.00–1.02
Metabolic syndrome 7.35 0.16 <.001 5.35–10.13
Type 2 diabetes 5.71 0.24 <.001 1.83–3.88
High blood pressure 10.82 0.20 <.001 7.24–16.18
Rheumatoid factor 0.86 0.16 .353 0.62–1.18
Anti-citrullinated protein antibodies 0.96 0.15 .79 0.71–1.29
Disease duration 1.02 0.08 .001 1.01–1.04
Remission 0.45 0.23 .001 0.29–0.71
Low disease activity 0.68 0.21 .077 0.45–1.04
Moderate disease activity 0.79 0.16 .141 0.58–1.08
High disease activity 2.85 0.16 <.001 2.07–3.92
Joint surgery 0.93 0.25 .72 0.55–1.51
Radiographic damage 0.98 0.15 .88 0.72–1.31
Extra-articular disease 1.42 0.19 .07 0.98–2.07
Multivariate analysis OR SE P CI 95%
Gender 0.84 0.31 .163 0.87–2.34
Age 1.06 0.01 <.001 1.05–1.09
Total cholesterol 1.01 0.02 .138 0.99–1.02
Triglycerides 1.01 0.02 .116 1.00–1.01
Metabolic syndrome 3.41 0.23 <.001 2.16–5.40
Type 2 diabetes 0.57 0.29 .205 0.39–1.23
High blood pressure 3.71 0.27 <.001 2.23–6.17
Disease duration 1.01 0.01 .199 0.99–1.09
Remission 0.84 0.31 .587 0.46–1.55
High disease activity 2.11 0.23 .001 1.35–3.32
Bolded values indicate statistically significant results (P<0.05).
CI= confidence interval, OR=odds ratio.
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Although the well-known role of the smoking habit in RA
pathogenesis, its impact on CVEs and subclinical atherosclerosis,
during RA, have still not been identified and the “smoking
paradox” has been proposed.[35–37] The weaker association
between smoking habit and both CVEs and subclinical
atherosclerosis might be related with an “index event” bias, in
which causal factors appear not to apply to disease complica-
tions, during observational and epidemiological studies.[38] We
did not observe any role of hypercholesterolemia in RA CVEs. In
fact, despite of the increased CV risk observed during this disease,
the rheumatoid pro-inflammatory process may induce a decrease
of serum total cholesterol, the so called RA lipid paradox.[39] This
result confirms that quantitative analyses might not identify the
real impact of cholesterol on CV comorbidities in RA. In fact, the
systemic inflammation modulates specific qualitative changes in
lipoproteins, mainly affecting the HDL fraction, which loses its
anti-inflammatory activity and its skill to reverse cholesterol
transport function.[40,41] On these bases, further studies are
needed to fully clarify the role of lipoproteins in inducing CVEs in
RA patients.
The inflammatory process strongly modulates all stages of the
atherosclerosis, including endothelial damage, plaque formation,
destabilization, and, finally, the thrombogenic events leading to
occlusion.[42] Many pathogenic pathways are activated in this
complex process including, endothelial cell dysfunction, oxida-
tive stress, pro-thrombotic phenotype, and pro-atherogenic
metabolic effects.[15,16] Taken together all these data confirm
that the pro-inflammatory process, associated with a dysregu-
lation of immune system, is strongly involved in the development
of accelerate atherosclerosis in RA.[43–47] In our observational
study, we observed that the high disease activity was significantly
associated with the evidence of both CVEs and subclinical
atherosclerosis. In fact, it has been shown that patients with
history of MI had more tender joints, worse fatigue, and higher
ESR levels.[37] As far as the relationship between disease duration
and CVEs are concerned, our study did not find any statistical
association. Although conflicting data are reported in available
literature, concerning the association between disease duration
and CV risk,[48,49] our results show that inflammatory burden
more than duration of the disease, contributes to the development
of CVEs. Taking together our data, we may suggest that not only
the management of traditional CV risk factor but also a good
control of disease activity, may play an important role in
preventing the CVEs and thus premature death in RA
patients.[43,48,50]
Ourmulticenter study carries out some limitations. The specific
design of our study, in which the different therapeutic strategies
of RA patients were not randomized, did not allow us to analyze
the possible association between treatments and outcomes, to
avoid the risk of a “confounding by indication” bias.[51–53]
However, it must be pointed out that a large percentage of our
patients were treated with CCSs. Although the available data are
conflicting, because of deleterious effects of CCSs, such as
disturbances of lipid and glucose metabolism and increase in
blood pressure, might be, at least in this setting, counteracted by
the anti-inflammatory properties of this family of medications,
the possible pro-atherogenic role of such drugs should be taken
into account in the management of these patients.[54,55] In fact, it
has been reported that a sustained exposure to CCSs was
significantly associated with cardiometabolic comorbidities in
rheumatic diseases, thus contributing to increased CV risk.[56–60]
Although a growing body of evidence suggests new possible
therapeutic targets in rheumatic diseases,[61–64] future specific
designed studies are needed to entirely elucidate this issue,
considering, even today, the central role of CCSs “bridging”
therapy in management of these patients.[65] Furthermore, due to
a higher value of missing data concerning body mass index
(BMI), we could not evaluate its impact on CVEs and subclinical
atherosclerosis. However, it has been shown that during RA, in
which sarcopenia may alter the body composition, BMI may not
be considered a valid predictor of CVEs and subclinical
atherosclerosis, as in normal population.[66–68]
In conclusion, inourknowledge, this is thefirstmulticenter study
on subclinical and clinical atherosclerosis in patients with RA,
throughout the whole country and not limited to some specific
geographic area. We pointed out a low prevalence of both
subclinical atherosclerosis and history of CV events when
compared with other available series. Nonetheless, a high disease
activity and presence of cardiovascular risk factors were found to
play a role to RA patients similarly from other countries. Our
results show that high values of DAS28 are associated with CVEs
and subclinical atherosclerosis, confirming the need of optimal
control of the disease activity in order to decrease the burden ofCV
comorbidities. Furthermore, the presence of HBP and MS were
significantly associated with CVEs and subclinical atherosclerosis,
confirming the some traditional CV risk factorsmay play a specific
role in modulating CV complications, during RA, and showing
that the risk forCVEs in Italian populationparallelswhat observed
in other countries. Future longitudinal analyses, on larger cohorts
of patients, with longer follow-up, are surely needed in order to
reinforce these data and suggest new research fields.
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